LONDON, Oct 25 (Reuters) - China-based cancer and immunology drug specialist Hutchison China MediTech, or Chi-Med, said it aimed to offer $262 million of American Depositary Shares, subject to market conditions, to help fund development of its pipeline.
from Reuters: New Issues News http://ift.tt/2y53TZp
Tidak ada komentar:
Posting Komentar